✦ LIBER ✦

A Feasibility Study of Bevacizumab plus Dose-Dense Doxorubicin–Cyclophosphamide (AC) Followed by Nanoparticle Albumin–Bound Paclitaxel in Early-Stage Breast Cancer

✍ Scribed by Sikov, W.M.; Sinclair, N.

Book ID: 123198950
Publisher: Elsevier Science
Year: 2012
Tongue: English
Weight: 63 KB
Volume: 23
Category: Article
ISSN: 1043-321X
DOI: 10.1016/j.breastdis.2012.06.009

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Dose-dense doxorubicin and cyclophospham

Dose-dense doxorubicin and cyclophosphamide followed by dose-dense albumin-bound paclitaxel plus bevacizumab is safe as adjuvant therapy in patients with early stage breast cancer

✍ John Pippen; Devchand Paul; Svetislava Vukelja; Alicia Clawson; Jose Iglesias 📂 Article 📅 2011 🏛 Springer US 🌐 English ⚖ 417 KB

Adjuvant dose-dense doxorubicin plus cyc

Adjuvant dose-dense doxorubicin plus cyclophosphamide followed by dose-densenab-paclitaxel is safe in women with early-stage breast cancer: a pilot study

✍ Nicholas Robert; Lea Krekow; Chris Stokoe; Alicia Clawson; Jose Iglesias; Joyce 📂 Article 📅 2010 🏛 Springer US 🌐 English ⚖ 199 KB

0151 Adjuvant dose-dense adriamycin plus

0151 Adjuvant dose-dense adriamycin plus cytoxan followed by dose-dense nab-paclitaxel is safe in women with early-stage breast cancer: A pilot study

✍ J. Pippen; J. O'Shaughnessy; S. Ambro; L. Krekow; C. Stokoe; P. Bhar; J. Iglesia 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 54 KB

A pilot study of adjuvant nanoparticle a

A pilot study of adjuvant nanoparticle albumin-bound (nab) paclitaxel and cyclophosphamide, with trastuzumab in HER2-positive patients, in the treatment of early-stage breast cancer

✍ Denise Yardley; Howard Burris; Nancy Peacock; Eric Raefsky; Marianne Melnik; Rog 📂 Article 📅 2010 🏛 Springer US 🌐 English ⚖ 171 KB

5034 Troponin I and C-reactive protein a

5034 Troponin I and C-reactive protein as biomarkers for changes in left ventricular ejection fraction in patients with early stage breast cancer treated with dose-dense doxorubicin and cyclophosphamide (AC) followed by weekly paclitaxel with trastuzumab and lapatinib

✍ P.G. Morris; C. Chen; N. Lin; B. Moy; S. Come; A. Abbruzzi; E. Winer; L. Norton; 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 50 KB

Impact of the Addition of Carboplatin an

Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance)

✍ Sikov, William M. (author);Berry, Donald A. (author);Perou, Charles M. (author); 📂 Article 📅 2015 🏛 American Society of Clinical Oncology 🌐 English ⚖ 288 KB